PDF icon Role of PARP Inhibitors in Metastatic Breast Cancer.pdfObjectives

After participating in this educational activity, attendees should be able to:
1. Describe poly-ADP-ribose polymerase (PARP) inhibitors mechanism of action.
2. Evaluate PARP inhibitor role in treatment for BRCA1/2+ metastatic breast cancer.
3. Review a patient case of metastatic breast cancer.

4. Apply available literature to clinical practice.



Catie Chatowsky, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.


Session date: 
01/07/2019 - 2:00pm to 3:00pm EST
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
United States
  • 1.00 ACPE Contact Hours

Please login or register to take this course.